Video index
1. Call to order
2. Consideration of revised draft Drug Utilization Review Board (DURB) Bylaws (Part 1 of 3)
3. Consideration of January 26, 2024, draft meeting minutes (Part 1 of 2)
4. Reconsideration of October 13, 2023, draft revised meeting minutes, limited to correcting the vote determination for agenda item 4j (Part 1 of 2)
5. House Bill 3286, 88th Texas Legislature, Regular Session (2023), update 6-.9.PJ.)
6. Open Meetings Act overview
7. Public comment and discussion on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL)
8. Public comment and discussion on single new drugs to be reviewed for the Medicaid PDL
9. Therapeutic and clinical drug reviews and updates: Gainwell Technologies
2. Consideration of revised draft Drug Utilization Review Board (DURB) Bylaws (Part 2 of 3)
3. Consideration of January 26, 2024, draft meeting minutes (Part 2 of 2)
4. Reconsideration of October 13, 2023, draft revised meeting minutes, limited to correcting the vote determination for agenda item 4j (Part 2 of 2)
10. Executive work session
11. Announcements of drugs recommended for the Medicaid PDL: Gainwell Technologies
12. Retrospective drug utilization review (DUR): Acentra Health
13. Prospective prior authorization proposals: Acentra Health
14. Retrospective drug use criteria for outpatient use in Vendor Drug Program
2. Consideration of revised draft Drug Utilization Review Board (DURB) Bylaws (Part 3 of 3)
15. Review of action items for next meeting: July 26,2024, 9:00 a.m.
Apr 26, 2024 Drug Utilization Review Board (DURB) Agenda
Full agenda
Share this video
Video Index
Full agenda
Share
1. Call to order
2. Consideration of revised draft Drug Utilization Review Board (DURB) Bylaws (Part 1 of 3)
3. Consideration of January 26, 2024, draft meeting minutes (Part 1 of 2)
4. Reconsideration of October 13, 2023, draft revised meeting minutes, limited to correcting the vote determination for agenda item 4j (Part 1 of 2)
5. House Bill 3286, 88th Texas Legislature, Regular Session (2023), update 6-.9.PJ.)
6. Open Meetings Act overview
7. Public comment and discussion on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL)
8. Public comment and discussion on single new drugs to be reviewed for the Medicaid PDL
9. Therapeutic and clinical drug reviews and updates: Gainwell Technologies
2. Consideration of revised draft Drug Utilization Review Board (DURB) Bylaws (Part 2 of 3)
3. Consideration of January 26, 2024, draft meeting minutes (Part 2 of 2)
4. Reconsideration of October 13, 2023, draft revised meeting minutes, limited to correcting the vote determination for agenda item 4j (Part 2 of 2)
10. Executive work session
11. Announcements of drugs recommended for the Medicaid PDL: Gainwell Technologies
12. Retrospective drug utilization review (DUR): Acentra Health
13. Prospective prior authorization proposals: Acentra Health
14. Retrospective drug use criteria for outpatient use in Vendor Drug Program
2. Consideration of revised draft Drug Utilization Review Board (DURB) Bylaws (Part 3 of 3)
15. Review of action items for next meeting: July 26,2024, 9:00 a.m.
Link
Start video at
Social
Embed
<iframe title="Swagit Video Player" width="640" height="360" src="https://texashhsc.v3.swagit.com/videos/303852/embed" frameborder="0" allowfullscreen></iframe>
Disable autoplay on embedded content?
Download
Download
Download Selected Item
